
UroGen Shares ENVISION Trial Subgroup Analysis on Tumor Burden and UGN-102 Response
UroGen Shares ENVISION Trial Subgroup Analysis on Tumor Burden and UGN-102 Response UroGen Pharma Ltd. (Nasdaq: URGN) announced results from subgroup analyses of the pivotal ENVISION study, assessing the impact…